Intervention

LHRHa

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting0

Common conditions2

Lead sponsors shown4

Clinical trials

4 shown

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate CancerNCT04557059 · 2020-11-12

ACTIVE_NOT_RECRUITING

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and EnzalutamideNCT01946165 · 2013-10-31

Mild Cognitive Impairment in Men Following Androgen DeprivationNCT01691976 · 2012-10-01

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate CancerNCT01088529 · 2009-12-01

Common conditions

Prostate Cancer3 Prostatic Neoplasms1

Leading sponsors

Cougar Biotechnology, Inc.1 Imperial College London1 Janssen Pharmaceutica N.V., Belgium1 M.D. Anderson Cancer Center1

Trial status mix

COMPLETED2

ACTIVE_NOT_RECRUITING1

WITHDRAWN1

Phase mix

PHASE22

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.